Amisulpride

CTX Lifesciences, is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Amisulpride API with Cas # 71675-85-9. We are a leading exporter of Amisulpride API with Cas # 71675-85-9. We are a trusted supplier with API exports in more than 87 Countries including the US, Europe, Brazil, Latin America,  China, Korea,Iran, Middle East and other emerging markets.

Amisulpride API, a medication, in the treatment of schizophrenia, acute psychotic episodes, depression, and nausea and vomiting. They specifically use it at lower doses intravenously to prevent and treat postoperative nausea and vomiting. In low doses by mouth to treat depression; and at higher doses by mouth to treat psychosis.

Healthcare professionals indicate Amisulpride for use in the United States in adults to prevent postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. It is indicated to treat PONV in patients who have received antiemetic prophylaxis with an agent of a different class . In other case or to who have not received prophylaxis.

Amisulpride works by blocking, or antagonizing, the dopamine D2 receptor, which reduces its signaling. It effectively treats dysthymia & the negative symptoms of schizophrenia by blocking the presynaptic dopamine D2 and D3 autoreceptors.

CTX also offers other Anti-Psychotic API such as Brexpiprazole and Anti-Emetic API i.e Ondansetron Hydrochloride.

Amisulpride API with Cas # 71675-85-9, is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

CTX supplies multiple pharmacopeial grades of its APIs, each tailored to customer requirements. Every product comes with a complete Drug Master File (DMF) to support regulatory submissions to global health authorities.

To ensure reliable quality, CTX maintains full backward integration. We manufacture key starting materials and intermediates in-house, giving us greater control over quality, supply consistency, and traceability. This approach also allows us to scale production quickly whenever customers face sudden demand spikes.

Our APIs deliver uniform performance batch after batch. We tightly control polymorphic form, impurity profile, particle size distribution, and stability parameters. Each product contains very low nitrosamine levels and undergoes a thorough assessment for genotoxic impurities, ensuring high purity and global regulatory compliance.

Sustainability and safety guide our operations from end to end. CTX runs in-house ETP, MEE, and ATFD systems to manage all effluents responsibly and meet every environmental requirement set by government authorities.